E-Mail
An early study of a new experimental drug to treat obesity known as cagrilintide shows that, when combined with semaglutide 2.4 mg, the combination leads to more weight loss than semaglutide 2.4 mg alone and is well tolerated. This phase 1 study, which was recently published in
The Lancet will be presented at this year s European Congress on Obesity (held online, 10-13 May) by Dr Lone Enebo, Novo Nordisk A/S, Denmark, on behalf of her colleagues. Novo Nordisk A/S is the manufacturer of both drugs in this study.
Combining medications with different modes of action may provide more effective treatment options for people with obesity. Weekly injections of cagrilintide, a newly-developed long-acting amylin analogue, in combination with semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist (already approved for type 2 diabetes), are both under clinical development for weight management. The efficacy and safety of semaglutide to treat obesity has been shown i
Share this article
Share this article
BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, and beneficial effects on weight related and health related quality of life scores (HRQoL) compared to placebo. Following the 68-week treatment period, more than half of participants had improved quality of life scores, indicating better physical function and improved psychological wellbeing.
Experts from the University Federico II of Naples, Italy analysed 147 middle aged obese people, examining the time they wake in the morning and go to bed at night.
‘Wonder’ jab that stops cravings could help you lose weight and fight obesity
13 May 2021, 10:14
Updated: 13 May 2021, 16:22
Invalid Date,
A WONDER jab that stops food cravings could soon help people lose weight.
People given the jab as part of a study rapidly dropped the pounds and ate less buffet food because their appetite was suppressed.
1
People given a weekly dose of semaglutide had a lower appetite and cravings for foodCredit: Alamy
If approved for use by medicine regulators, it could be a game-changer for people who can t fight the flab - and the obesity crisis.
More than 650 million people worldwide are obese, which can increase the risk for heartdisease, type 2 diabetes and more.
1.2-mg cagrilintide: 15.7% drop in body weight from baseline
2.4-mg cagrilintide: 17.1% drop
4.5-mg cagrilintide: 15.4% drop
In comparison with placebo plus semaglutide, 1.2 mg, 2.4 mg, and 4.5 mg of cagrilintide plus semaglutide all resulted in significantly greater estimated treatment differences for change in baseline body weight.
Doses of 0.16 mg (8.3% drop in baseline body weight), 0.30 mg (10% drop), and 0.60 mg (10.6% drop) of cagrilintide plus 2.4-mg semaglutide all yielded slightly greater drops in baseline body weight versus placebo plus semaglutide, although the differences weren t statistically significantly.
Across the board, glycemic parameters showed improvement in all treatment groups regardless of the cagrilintide dose.
These findings built upon a previous phase II monotherapy trial, initially presented at the 2020 virtual ObesityWeek, which met its primary endpoint showing a 10.8% weight loss at week 26 with 4.5-mg cagrilintide compared with a 3% weight loss w